Artificial intelligence | Pharmaceuticals | Regulatory Rapporteur

Skip to main content
Skip to navigation

Artificial intelligence articles

MD2/IVD2: Unravelling AI as a medical device - Insights into the EU AI Act and other global perspectives

2024-11-08T06:56:00+00:00By Margareth Jorvid

Breaking barriers: the future of CMC powered by AI
2024-10-11T10:24:00+01:00By Mariam Amer, Eric Kelly, George Oliarnyk and Tiejun Wang
Unveiling the synergy of AI’s regulatory harmony in shaping the future of biopharmaceutical progress
2024-04-03T12:00:00+01:00By Baily Thomas, Madison Burns, Danielle Helton Corwin and Eddie Reilly
Developing a digital people strategy to harness the power of generative AI
2024-02-09T16:30:00+00:00By Sarah Chan, Danielle McVey and of the TOPRA RegOps SPIN group
Sink or swim: the changing tides of device regulation
2024-02-08T00:05:00+00:00By Esteban Herrero-Martinez and Dejan Brkic
Chemical characterisation: a critical first step for medical device development
2024-02-08T00:05:00+00:00By Jocivania Oliveira da Silva and Marielle Fournier
Overview of medical device regulations in Canada
2024-02-08T00:05:00+00:00By Hasnaa Fatehi

AI meets medtech:
big opportunities
require a
measured approach
2024-02-08T00:05:00+00:00By Jacques du Preez
EU MDR implementation – what is changing for the medical device industry?
2024-02-08T00:05:00+00:00By Ravi Mishra, Vivek Singh Bhagoor, Dharti Shah, Pinki Mishra, Harika Potta, Vesna Sevaljevic, Branislav Radivojevic, Deepti Jagga, Scott Krygier, Vivek Tomar and Allison Gillespie
The increasing complexity of biological medicinal products
2024-01-05T00:05:00+00:00By Julie Warner and and Ash Ramzan
Artificial intelligence in drug discovery
2024-01-05T00:05:00+00:00By Paula Maguire, Bruno Speder and Liam Tremble

More AI stories